🇺🇸 FDA
Pipeline program

S1RA plus NMDAE

CMUH112-REC3-202

Phase 2 small_molecule active

Quick answer

S1RA plus NMDAE for Schizophrenia is a Phase 2 program (small_molecule) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indication
Schizophrenia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials